San Francisco, December 4, 2024 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced the filing of a new international patent application with the potential of significantly improving administration of the company’s lead drug candidate Dutogliptin.
Recardio has filed a new international PCT application, published as WO2023/208876 on 2 November 2023. The application relates to a novel formulation process of the company’s lead drug candidate Dutogliptin and was developed by the company in the past years.
Compared to the current daily application mode, this new formulation will enable a once per week administration in the targeted therapeutic setting and beyond, resulting in potential significant easy use and compliance benefits for the patients.
Recardio is in the process of converting this new international application globally into national patent applications in key markets and by this, extending the patent protection for Dutogliptin into 2043.
About Recardio
Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.
Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction. This trial is planned to initiate in 2025 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.
For more information, visit: www.recardio.eu or contact pr@recardio.eu